Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 3 | 2021 | 46 | 1.560 |
Why?
|
| Oncologists | 2 | 2021 | 29 | 1.390 |
Why?
|
| Intestinal Obstruction | 2 | 2021 | 94 | 1.250 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2024 | 237 | 1.080 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 106 | 1.060 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 418 | 1.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2022 | 183 | 0.710 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2021 | 17 | 0.710 |
Why?
|
| Informed Consent | 1 | 2022 | 334 | 0.670 |
Why?
|
| Cancer Survivors | 2 | 2018 | 200 | 0.590 |
Why?
|
| Cesarean Section | 2 | 2025 | 387 | 0.580 |
Why?
|
| Pregnancy Tests | 1 | 2016 | 2 | 0.520 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2016 | 7 | 0.520 |
Why?
|
| Hydatidiform Mole | 1 | 2016 | 18 | 0.520 |
Why?
|
| Chorionic Gonadotropin | 1 | 2016 | 77 | 0.500 |
Why?
|
| Hemoperitoneum | 1 | 2015 | 8 | 0.500 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 358 | 0.490 |
Why?
|
| Papillomavirus Infections | 2 | 2024 | 291 | 0.480 |
Why?
|
| Postoperative Hemorrhage | 1 | 2015 | 84 | 0.470 |
Why?
|
| Phlebotomy | 1 | 2012 | 16 | 0.410 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1476 | 0.410 |
Why?
|
| Palliative Care | 3 | 2021 | 427 | 0.400 |
Why?
|
| Developed Countries | 1 | 2012 | 37 | 0.400 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2012 | 29 | 0.400 |
Why?
|
| Ultrasonography | 1 | 2015 | 931 | 0.350 |
Why?
|
| Developing Countries | 1 | 2012 | 270 | 0.350 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2018 | 53 | 0.290 |
Why?
|
| Balloon Occlusion | 1 | 2025 | 47 | 0.230 |
Why?
|
| Female | 13 | 2025 | 66330 | 0.230 |
Why?
|
| Blood Loss, Surgical | 1 | 2025 | 154 | 0.220 |
Why?
|
| Specimen Handling | 1 | 2024 | 142 | 0.220 |
Why?
|
| Hysterectomy | 1 | 2025 | 191 | 0.210 |
Why?
|
| Self Care | 1 | 2024 | 210 | 0.210 |
Why?
|
| Feasibility Studies | 2 | 2016 | 747 | 0.210 |
Why?
|
| Placenta Accreta | 1 | 2025 | 157 | 0.200 |
Why?
|
| Humans | 16 | 2025 | 124297 | 0.200 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 121 | 0.190 |
Why?
|
| Herpesviridae Infections | 1 | 2023 | 142 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 418 | 0.170 |
Why?
|
| Chicago | 1 | 2020 | 21 | 0.170 |
Why?
|
| Social Environment | 1 | 2018 | 120 | 0.140 |
Why?
|
| Pain | 1 | 2021 | 449 | 0.140 |
Why?
|
| Violence | 1 | 2018 | 116 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 35 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 429 | 0.140 |
Why?
|
| Communication | 1 | 2021 | 506 | 0.140 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1085 | 0.140 |
Why?
|
| Adult | 6 | 2025 | 29377 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 274 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2020 | 543 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 868 | 0.130 |
Why?
|
| Pregnancy | 3 | 2025 | 7180 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 1137 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 368 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2025 | 16299 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 605 | 0.100 |
Why?
|
| Acetic Acid | 1 | 2012 | 18 | 0.100 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2012 | 7 | 0.100 |
Why?
|
| Hyperbilirubinemia | 1 | 2012 | 41 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2012 | 48 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 1650 | 0.100 |
Why?
|
| Unnecessary Procedures | 1 | 2012 | 58 | 0.100 |
Why?
|
| Bilirubin | 1 | 2012 | 123 | 0.100 |
Why?
|
| Triage | 1 | 2012 | 137 | 0.090 |
Why?
|
| Papillomavirus Vaccines | 1 | 2012 | 94 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6467 | 0.090 |
Why?
|
| Middle Aged | 5 | 2024 | 26620 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 509 | 0.080 |
Why?
|
| Neoplasms | 1 | 2023 | 2764 | 0.080 |
Why?
|
| Aged | 3 | 2021 | 19558 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5131 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2015 | 6123 | 0.060 |
Why?
|
| Hospitals, Urban | 1 | 2024 | 99 | 0.060 |
Why?
|
| Operative Time | 1 | 2025 | 171 | 0.060 |
Why?
|
| Postpartum Hemorrhage | 1 | 2025 | 96 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12289 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2025 | 309 | 0.050 |
Why?
|
| Young Adult | 1 | 2016 | 9004 | 0.050 |
Why?
|
| HIV Infections | 1 | 2012 | 1891 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2021 | 120 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1369 | 0.040 |
Why?
|
| Neutropenia | 1 | 2021 | 200 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 222 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2012 | 8190 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 793 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 353 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 40 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2021 | 316 | 0.040 |
Why?
|
| Texas | 1 | 2024 | 3585 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 866 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 998 | 0.030 |
Why?
|
| Male | 1 | 2015 | 61050 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5818 | 0.020 |
Why?
|